12 Children Were Born Deaf. 11 Can Hear Now. Five Teams Are Racing to Sell the Cure.
Regeneron's CHORD trial restored hearing in 11 of 12 children with OTOF gene mutations. Three achieved normal hearing levels. Competing programs in Shanghai and Paris are close behind. An original cost analysis compares gene therapy against a lifetime of cochlear implants, and the math is closer than you would expect.
Eleven out of twelve. That is the response rate from Regeneron's pivotal CHORD trial, published in the New England Journal of Medicine in October 2025. Twelve children, aged 10 months to 16 years, born with profound deafness caused by mutations in the OTOF gene, received a one-time injection of DB-OTO, an adeno-associated virus (AAV) dual-vector gene therapy. Within weeks, 11 of them could hear. Three reached normal hearing thresholds. Six could detect soft speech without any device. Three could hear whispers.
One child who initially did not respond crossed into near-normal hearing sensitivity by week 48. Among the eight patients followed beyond 36 weeks, hearing improvements remained stable or continued to get better through 72 weeks of observation. No therapy-related serious adverse events occurred.
Regeneron is not alone. At least four other programs are pursuing the same gene, the same protein, and the same patient population across three continents. A regulatory filing is expected in 2026. If approved, DB-OTO would become the first gene therapy to cure a form of deafness. But the story underneath that headline is more complicated than it appears.
Why OTOF, and Why Now
Otoferlin is a protein encoded by the OTOF gene. It sits at the synapse between inner hair cells and auditory nerve fibers. Without it, sound waves can vibrate the cochlea perfectly, but the electrical signal never reaches the brain. Children with biallelic OTOF mutations are born into silence. Their inner ears work mechanically. Their nervous system is intact. Only the chemical handoff between the two is broken.
According to a comprehensive review in Genes (2020), OTOF mutations account for 1% to 8% of all congenital hearing loss cases, depending on the population studied. In the United States, where roughly 1 in 500 newborns has significant hearing loss, that translates to approximately 50 to 200 OTOF-affected births per year. Globally, congenital hearing loss affects an estimated 34 million children according to the World Health Organization. Even at the low end of 1%, OTOF mutations represent hundreds of thousands of affected individuals worldwide.
OTOF became the first target for inner ear gene therapy for a specific molecular reason: the defect is clean. Hair cells are structurally intact. The auditory nerve is functional. Deliver a working copy of the gene, and the entire pathway can switch on. More than 430 genes are now linked to hearing loss, but most involve structural or developmental abnormalities that cannot be reversed by adding a single missing protein.
A second reason is technical. Full-length OTOF is approximately 6 kilobases, too large for a single AAV vector (capacity roughly 4.7 kb). Multiple groups solved this by splitting the gene across two AAV vectors and relying on recombination inside the cell to produce the full-length protein. That dual-vector approach, first demonstrated in mice, is now the backbone of every clinical program in the field.
Five Programs, Three Continents
| Program | Sponsor | Location | Patients Treated | Key Result | Publication |
|---|---|---|---|---|---|
| DB-OTO (CHORD) | Regeneron / Decibel | US, UK | 12 | 11/12 improved; 3 normal hearing | NEJM Oct 2025 |
| AAV1-hOTOF (binaural) | Shanghai Fudan / REFRESH | China | 5 | 5/5 bilateral restoration + speech | Nature Medicine Jun 2024 |
| AAV1-hOTOF (unilateral) | Shanghai Fudan / Otojoy | China | 6 (+ 1 bilateral) | Hearing restoration, speech development | Lancet 2024 |
| SENS-501 (Audiogene) | Sensorion | France, Australia | 6 | Early improvement signals at 3 months | Company data Aug 2025 |
| AK-OTOF | Akouos / Eli Lilly | US | Enrolling | Phase 1/2 ongoing | ClinicalTrials.gov |
Regeneron's program is the furthest along by conventional regulatory standards. DB-OTO carries orphan drug, rare pediatric disease, fast track, and regenerative medicine advanced therapy (RMAT) designations from the FDA. Regeneron stated in October 2025 that a regulatory application was planned for "later this year," making a 2026 filing likely.
But the Chinese programs published first. A team led by Yilai Shu at Fudan University's Eye & ENT Hospital in Shanghai reported in Nature Medicine in June 2024 that five children treated with binaural dual-AAV1 gene therapy all achieved bilateral hearing restoration, speech recovery, and sound source localization. All five. A separate publication in The Lancet from the same institution reported similar results in six unilateral and one bilateral patient.
Sensorion's SENS-501, based in France with trial sites also in Australia, is notable for a different reason. Its Audiogene trial exclusively enrolls infants and toddlers aged 6 to 31 months who have never received cochlear implants. This is, by design, the youngest cohort in the field, targeting the critical window of brain plasticity when auditory cortex development is most receptive. Six patients have been treated across two dose cohorts with no serious adverse events.
An Original Cost Comparison: Gene Therapy vs. Cochlear Implants
Until now, the standard treatment for OTOF-related deafness has been cochlear implantation. Cochlear implants bypass the broken synapse entirely, converting sound into electrical signals delivered directly to the auditory nerve. They work. Roughly 1 million people worldwide use them. But they are not hearing. They are a digital approximation of hearing, requiring external hardware, batteries, software updates, and periodic surgical revisions.
Here is a cost comparison nobody has published, built from the best available data:
| Cost Component | Cochlear Implant (bilateral, lifetime) | Gene Therapy (estimated) |
|---|---|---|
| Surgery | $60,000-$100,000 (two ears) | $15,000-$30,000 (round window injection) |
| Device / therapy | $40,000-$60,000 (two processors) | $500,000-$2,000,000 (gene therapy pricing precedent) |
| Rehabilitation | $20,000-$40,000 (speech therapy, mapping) | $5,000-$15,000 (hearing adaptation, speech therapy) |
| Maintenance (60 years) | $120,000-$300,000 (replacements, batteries, upgrades) | $0 (if durable) |
| Total (nominal) | $240,000-$500,000 | $520,000-$2,045,000 |
Cochlear implant cost estimates draw from a 2024 systematic review in Otology & Neurotology and UCSF's published cost breakdowns. Gene therapy pricing uses precedents from Zolgensma ($2.1M), Hemgenix ($3.5M), and Casgevy ($2.2M), discounted because OTOF-related deafness, while rare, has a larger eligible population than some of those conditions.
At face value, cochlear implants win on cost. But two factors complicate the comparison. First, gene therapy is a one-time intervention. If hearing restoration proves durable beyond the current 72-week follow-up, total cost of ownership shifts. A child implanted at age one will need device upgrades, processor replacements, and potential surgical revisions across a 70-year lifespan. Discounting those future costs to present value at 3% narrows the gap: the $240,000-$500,000 nominal lifetime CI cost has a present value closer to $120,000-$250,000, while gene therapy's front-loaded cost stays the same. Second, natural acoustic hearing differs qualitatively from cochlear implant hearing. Music perception, speech comprehension in noisy environments, and spatial sound localization are all meaningfully better with biological hearing. No published cost-effectiveness analysis yet captures that quality-of-life difference.
If gene therapy pricing lands at $500,000 and durability extends beyond 10 years, the lifetime economics approach parity with bilateral cochlear implantation. If it lands at $2 million, it becomes the most expensive hearing intervention in history for an exceedingly small patient population.
What the Data Does Not Show
Follow-up is short. Regeneron's longest observation is 72 weeks. Nobody knows whether restored hearing persists for 5 years, 10 years, or a lifetime. AAV-delivered transgenes typically integrate into nondividing cells and persist, but inner ear hair cells exist in a mechanically hostile environment. Long-term data simply does not exist yet.
Retreatment may be impossible. AAV vectors trigger an immune response. Once a patient receives AAV1, they develop neutralizing antibodies that block the same vector from working again. If hearing degrades after five years, a second injection of the same therapy will likely fail. Alternative serotypes or immunosuppression protocols could theoretically address this, but no such protocol has been tested in the cochlea.
No head-to-head trials exist between any of the five competing programs. Direct comparison of efficacy, safety, and durability across programs is currently impossible. Differences in AAV serotype, promoter design, surgical technique, and patient selection mean that each program's results are not interchangeable.
Generalizability is limited. OTOF is one of more than 430 genes linked to hearing loss. Most genetic deafness involves structural abnormalities (malformed cochleae, absent auditory nerves, degenerated hair cells) that cannot be fixed by adding a single protein. OTOF is the low-hanging fruit. Success here does not mean gene therapy will work for GJB2 (connexin 26, the most common deafness gene) or any other form of genetic hearing loss.
Strongest Case Against
Cochlear implants are available now, at every children's hospital in the developed world, for every form of severe to profound hearing loss regardless of genetic cause. They have more than 50 years of safety and efficacy data. Complication rates are well-characterized. Insurance coverage is established. Rehabilitation pathways are mature. A child implanted at 12 months can enter mainstream school on schedule.
Gene therapy, by contrast, targets only one genetic subtype (1-8% of cases), has unknown long-term durability, requires surgery under general anesthesia in infants, will cost multiples of what implants cost, cannot be readministered if it fails, and is being developed by pharmaceutical companies that have a poor track record of pricing gene therapies affordably. Bluebird bio's Zynteglo launched at $2.8 million and the company went bankrupt. Spark Therapeutics' Luxturna ($850,000 for inherited retinal dystrophy) has treated fewer than 200 patients in six years. The track record of ultra-rare gene therapies reaching the patients who need them is not encouraging.
There is a deeper objection. The framing of deafness as a deficiency to be corrected is itself contested. The National Association of the Deaf has a nuanced position on genetic research: supportive of informed choice, critical of language that pathologizes deaf identity. Many deaf adults who grew up with sign language, Deaf schools, and Deaf community do not experience their lives as broken. The "race to cure deafness" framing, which this article admittedly adopts, carries assumptions about what constitutes a good life that not everyone shares. For families of newly diagnosed infants, these are not abstract philosophical debates. They are intensely personal decisions made under time pressure, and the medical system overwhelmingly steers toward intervention.
A family whose child is deaf today should not wait for a therapy that might be approved in 2027 and might be accessible in 2028. Cochlear implants, for all their limitations, deliver hearing now. Every month of delay in auditory stimulation during the critical period costs language development that may never be fully recovered.
What You Can Do
If your child is born with hearing loss, request genetic testing. Newborn hearing screening (mandated in all 50 U.S. states) identifies loss, but not the cause. A genetic panel costing $250-$1,500 can identify whether the deafness is caused by OTOF, GJB2, or another gene. Many families never learn the genetic basis of their child's deafness, which forecloses options before they are considered.
If testing reveals OTOF mutations, ask your ENT or audiologist about clinical trial eligibility. Sensorion's Audiogene trial specifically enrolls infants who have not yet received cochlear implants. Regeneron's program is further along. Both are actively recruiting. ClinicalTrials.gov lists all active studies under the search term "OTOF gene therapy."
Do not delay cochlear implantation while waiting for gene therapy approval. Brain plasticity for auditory development peaks before age 3 and declines sharply after age 5. If gene therapy is not available within your child's critical window, implants remain the right call. Sensorion is the only program explicitly designed around this timing constraint.
For policymakers and insurers: CMS is developing gene therapy payment models that spread costs over multiple years. Outcomes-based contracts, where manufacturers refund payment if the therapy fails, are being piloted for Zolgensma and Casgevy. These frameworks will matter enormously if OTOF gene therapy reaches the market at $1 million or above.
The Bottom Line
For the first time, profoundly deaf children have heard their parents' voices through biological hearing restored by gene therapy. Regeneron's CHORD trial produced a 92% response rate in a disease with a 0% natural recovery rate, published in the most rigorous medical journal in the world. Chinese teams achieved 100% bilateral restoration in smaller cohorts. Sensorion is targeting infants before cochlear implant decisions are made. At least five programs are active, and regulatory approval could come within 18 months.
But the eligible population is small (50-200 U.S. births per year), the price will be high ($500K-$2M if precedent holds), durability is unproven beyond 72 weeks, retreatment is likely impossible, and generalization to other deafness genes is uncertain. OTOF gene therapy will not end childhood deafness. It will end one very specific form of it, for families who can access it, if the economics work. For the 430+ other deafness genes, the cochlear implant remains the best tool humanity has built. For OTOF families, something better may finally be arriving.